August 11, 2017

Corcept Therapeutics

We feel like a lame duck on the markets.



CORT (ISIN: US2183521028)

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Market: Nasdaq

http://www.corcept.com


Gain over the last quarter: +36.3 % 

Fair value:  $ 16.5
Discount: 20%
Yield: N/A
Outperformer

Mind the valuta risk:

No comments:

Post a Comment